Wikipedia
Vantictumab
Vantictumab is a monoclonal antibody designed for the treatment of cancer.
This drug was developed by OncoMed Pharmaceuticals Inc.
It targets the frizzled receptors on cancer cells.
In 2016 results were reported from a phase 1b clinical trial for triple-negative breast cancer.